Syngene locks in Bristol Myers Squibb alliance through 2035
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
Subscribe To Our Newsletter & Stay Updated